Logo image of TH.CA

THERATECHNOLOGIES INC (TH.CA) Stock Price, Quote, News and Overview

TSX:TH - Toronto Stock Exchange - CA88338H7040 - Common Stock - Currency: CAD

2.18  +0.04 (+1.87%)

TH.CA Quote, Performance and Key Statistics

THERATECHNOLOGIES INC

TSX:TH (2/5/2025, 7:00:00 PM)

2.18

+0.04 (+1.87%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.13
52 Week Low1.59
Market Cap100.24M
Shares45.98M
Float28.68M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE20.22
Earnings (Next)02-19 2025-02-19/amc
IPO12-21 1993-12-21


TH.CA short term performance overview.The bars show the price performance of TH.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

TH.CA long term performance overview.The bars show the price performance of TH.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TH.CA is 2.18 CAD. In the past month the price decreased by -24.31%. In the past year, price decreased by -0.46%.

THERATECHNOLOGIES INC / TH Daily stock chart

TH.CA Latest News, Press Releases and Analysis

News Image
a month ago - Theratechnologies

Theratechnologies Provides Update on EGRIFTA SV® Supply

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...

News Image
a month ago - Theratechnologies

Theratechnologies fait le point sur l’approvisionnement d’EGRIFTA SV(MD)

MONTRÉAL, 09 janv. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une...

News Image
2 months ago - Theratechnologies

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...

News Image
2 months ago - Theratechnologies

Theratechnologies soumet un supplément d'approbation préalable à la FDA pour l’environnement de la fabrication d’EGRIFTA SV(MD)

MONTRÉAL, 18 déc. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une...

TH.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
BCT.CA BRIACELL THERAPEUTICS CORP N/A 286.42M
FRX.CA FENNEC PHARMACEUTICALS INC N/A 267.56M
EDT.CA SPECTRAL MEDICAL INC N/A 161.22M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 156.37M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 95.36M
COV.CA COVALON TECHNOLOGIES LTD 27.36 82.47M
ONC.CA ONCOLYTICS BIOTECH INC N/A 80.92M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 80.27M
MBX.CA MICROBIX BIOSYSTEMS INC 16.67 67.27M
SVA.CA SERNOVA CORP N/A 56.39M
HBP.CA HELIX BIOPHARMA CORP N/A 44.12M
MDCX.CA MEDICUS PHARMA LTD N/A 41.77M

About TH.CA

Company Profile

TH logo image Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 103 full-time employees. The firm is focused on the development and commercialization of therapies addressing unmet medical needs. The company markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The firm's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Company Info

THERATECHNOLOGIES INC

2015 Peel Street, 11th Floor

MONTREAL QUEBEC H3A 1T8 CA

CEO: Paul Levesque

Employees: 103

Company Website: https://www.theratech.com/

Investor Relations: https://www.theratech.com/investors/

Phone: 15143367800

TH.CA FAQ

What is the stock price of TH.CA?

The current stock price of TH.CA is 2.18 CAD.


What is the symbol for THERATECHNOLOGIES INC stock?

The exchange symbol of THERATECHNOLOGIES INC is TH and it is listed on the Toronto Stock Exchange exchange.


On which exchange is TH.CA stock listed?

TH.CA stock is listed on the Toronto Stock Exchange exchange.


Is TH.CA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TH.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TH.CA.


Does TH.CA stock pay dividends?

TH.CA does not pay a dividend.


When does TH.CA stock report earnings?

TH.CA will report earnings on 2025-02-19, after the market close.


What is the Price/Earnings (PE) ratio of TH.CA?

TH.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).


TH.CA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to TH.CA. When comparing the yearly performance of all stocks, TH.CA turns out to be only a medium performer in the overall market: it outperformed 65.19% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TH.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TH.CA. TH.CA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TH.CA Financial Highlights

Over the last trailing twelve months TH.CA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by 91.87% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -4.53%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%300%
Sales Q2Q%8.37%
EPS 1Y (TTM)91.87%
Revenue 1Y (TTM)5.75%

TH.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to TH.CA. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 103.61% and a revenue growth 1.81% for TH.CA


Ownership
Inst Owners25.25%
Ins Owners0.91%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84
Price Target6.02 (176.15%)
EPS Next Y103.61%
Revenue Next Year1.81%